Top ▲
| Quaternary Structure: Complexes |
| Interleukin-2 receptor |
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 272 | 10p15.1 | IL2RA | interleukin 2 receptor subunit alpha | |
| Mouse | 1 | 268 | 2 8.91 cM | Il2ra | interleukin 2 receptor, alpha chain | |
| Rat | 1 | 267 | 17q12.2 | Il2ra | interleukin 2 receptor subunit alpha | |
| Previous and Unofficial Names |
| CD25 | TAC antigen | IL2RAC | IL-2R alpha chain | Ly-43 | interleukin 2 receptor |
| Database Links |
|
| Alphafold | P01589 (Hs), P01590 (Mm), P26897 (Rn) |
| ChEMBL Target | CHEMBL1778 (Hs), CHEMBL3287 (Mm) |
| DrugBank Target | P01589 (Hs) |
| Ensembl Gene | ENSG00000134460 (Hs), ENSMUSG00000026770 (Mm), ENSRNOG00000047647 (Rn) |
| Entrez Gene | 3559 (Hs), 16184 (Mm), 25704 (Rn) |
| Human Protein Atlas | ENSG00000134460 (Hs) |
| KEGG Gene | hsa:3559 (Hs), mmu:16184 (Mm), rno:25704 (Rn) |
| OMIM | 147730 (Hs) |
| Pharos | P01589 (Hs) |
| UniProtKB | P01589 (Hs), P01590 (Mm), P26897 (Rn) |
| Wikipedia | IL2RA (Hs) |
Download all structure-activity data for this target as a CSV file 
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| IL2RA is a ligand binding component of the IL-2R complex. This subunit is the molecular target of the approved biologics daclizumab (including daclizumab beta) and basiliximab. Another anti-CD25 mAb, inolimomab, has received orphan drug designation from the EMA, for the treatment of graft-versus-host disease. Phase 3 findings for this drug and indication are reported in [2], the major conclusion being that the primary end point for the trial was not met (no statistical difference between the inolimomab and normal standard of care arms of the study). |
| Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
||
|
1. Queen CL, Schneider WP, Selick HE. (1997) Genetic engineering; complementarity zones. Patent number: US5693761. Assignee: Protein Design Labs, Inc.. Priority date: 28/12/1988. Publication date: 02/12/1997.
2. Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Bron D, Gard P et al.. (2017) A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood, 129 (5): 643-649. [PMID:27899357]
IL-2 receptor family: Interleukin-2 receptor subunit α. Last modified on 27/10/2017. Accessed on 16/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1695.
target has curated data in GtoImmuPdb
